JSPR
Jasper Therapeutics Inc
0.56$
-1.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
Jasper Therapeutics Inc (JSPR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -6.9 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.2 | 0.0 | 0.0 | -5.4 | -6.2 | -5.8 | -7.1 | -15 | -14 | -9.4 | -9.6 | -13 | -10 | -13 | -12 | -16 | -16 | -12 | -14 | -21 | -23 | -15 | -17 | -22 | -15 | -6.9 | -60 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.5 | 0.2 | 0.3 | 0.3 | 0.2 | 0.3 | 0.0 | 0.0 | 0.6 | |
| 0.0 | 0.0 | 0.0 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 | 0.8 | 1.1 | 0.6 | 1.6 | 1.3 | 1.4 | 1.4 | 1.2 | 1.2 | 1.5 | 2.0 | 2.0 | 1.8 | 1.8 | 1.4 | 1.7 | 0.4 | 0.8 | 4.3 | |
| -1.2 | 3.8 | 5.0 | – | 3.9 | 0.4 | 0.4 | 0.2 | -5.3 | -0.3 | 0.2 | 1.5 | 2.6 | 1.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.1 | 0.0 | 0.0 | 0.1 | -0.4 | 2.2 | 2.7 | -2.9 | -2.4 | 1.1 | 1.8 | -1.2 | 0.9 | 1.5 | 4.1 | -1.4 | -3.6 | 1.0 | 1.9 | 0.8 | -3.9 | 8.9 | -0.2 | -9.7 | -4.4 | 1.2 | -13 | |
| 1.0 | 1.0 | 1.0 | 0.0 | 1.0 | 0.3 | 0.5 | 0.7 | 0.0 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.2 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.1 | 0.0 | 0.1 | – | 0.1 | -0.3 | -0.5 | -0.7 | 0.0 | -0.2 | -0.2 | -0.1 | 0.0 | 0.0 | – | -0.2 | 0.0 | -0.2 | -0.3 | -0.1 | 0.0 | 0.0 | 0.1 | 0.1 | – | 0.1 | – | |
| – | – | – | – | – | – | 6.6 | -0.9 | 0.0 | – | – | 0.0 | 0.0 | 0.0 | – | 0.0 | – | – | 0.0 | 0.3 | – | 0.2 | – | -0.2 | – | 0.0 | – | |
| 0.0 | 11 | 11 | 11 | 11 | -0.6 | 92 | -0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 102 | -0.3 | 0.0 | -0.3 | 47 | 0.2 | 0.0 | 0.3 | 0.0 | 6.2 | 28 | -0.3 | – | 0.0 | – | |
| 1.1 | 0.0 | 0.0 | 5.4 | 3.6 | -0.3 | 84 | -16 | -14 | -9.6 | -9.9 | -13 | 91 | -14 | -12 | -17 | 32 | -12 | -14 | -21 | -23 | -9.3 | 11 | -22 | -15 | -6.8 | -32 | |
| -0.2 | 0.0 | 0.0 | -5.4 | -7.2 | -6.1 | -7.6 | -15 | -14 | -9.6 | -9.9 | -13 | -10 | -13 | -12 | -17 | -16 | -12 | -14 | -21 | -23 | -15 | -17 | -22 | -15 | -6.9 | -60 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.